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Editorial
Ovarian cancer (OC) is currently the 7th most common 
malignancy globally and the most lethal gynecological 
cancer.[1] It has been estimated that, in the United States, 
one woman in 70 will develop ovarian cancer, and one 
woman in 100 will die of the disease.[2] Ovarian cancer rates 
vary between different countries and appear to be related 
to socioeconomic status and reproductive factors. It is the 
second most common gynaecological cancer in sub Saharan 
Africa. Epithelial ovarian cancer (EOC) constitutes about 
85-90% of all ovarian malignancies.[1] In both developed and 
developing nations, the case fatality of ovarian cancer is very 
high for some reasons. The disease is associated with late 
presentation as there are no specific early symptoms to warn 
the patients and caregivers, there are no significant screening 
tests to predict patients who might develop the cancer and 
no matter how good the immediate outcomes following the 
current standard modalities of treatment which includes 
optimum debulking surgery and chemotherapy, recurrence 
is the rule rather than the exception in most cases.
Epithelial ovarian cancer arises through somatic and 
germ-line mutations. The sporadic somatic mutations account 
for majority of cases and this largely arise from the effects 
of advancing age and environmental factors and cannot be 
transferred to the offspring. Germ line mutation accounts 
for up to 10% of all ovarian cancers and up to 25% of EOC. 
Germ line mutation is inherited in an autosomal dominant 
fashion (maternal and paternal) and many members of 
the family are affected across several generations.[3] True 
hereditary ovarian cancer actually arises from BRCA1 and 
BRCA2 germ line mutations. A family history of ovarian and 
breast cancer particularly before the age of 50 years in first 
degree relations is a strong risk factor for BRCA1 and BRCA2 
mutations. Epithelial ovarian cancer is also a component 
of Lynch syndrome II (Hereditary nonpolyposis colorectal 
cancer syndrome-HNPCC). In addition to a predisposition 
to develop colorectal and endometrial cancer, women with 
this syndrome have a 10-13% lifetime risk for developing 
ovarian cancer.[3,4]
Given the high relapse rate and poor prognosis of high grade 
and advanced EOC, interest is increasing in new methods of 
treating the disease to improve the overall survival. Some 
of the evolving methods include targeted therapy using 
humanized monoclonal antibodies, immunotherapy, T-cell 
engineering etc.,[5,6] However, to apply these new treatment 
modalities, individual EOC has to be characterized in terms of 
its genetics and epigenetics. Several panels for such studies 
have been developed and currently been deployed for the 
investigation and management of patients.
Managing OC like all other malignancies is particularly 
challenging in sub Saharan Africa. Apart from the fact that 
the patients present in advanced stages, the majority of them 
cannot afford the cost of care since health financing is still 
largely out of pocket in most parts of the region. The cost of 
chemotherapy drugs is exorbitant and beyond the reach of 
most patients such that majority never complete their course 
of chemotherapy. Sometimes also because of the menace of 
fake and adulterated drugs pervading the region, those who 
receive chemotherapy show little or no improvement. The 
dearth of appropriately trained gynaecological oncologists 
in the region is another critical challenge.[7] Altogether, these 
make the care of patients with OC at best suboptimum in 
most parts of sub-Saharan Africa leading to more case fatality.
A lot of studies have been done in the white population to 
understand the population-based risk factors for ovarian 
cancer, the genetics and epigenetics of individual ovarian 
cancer is also been vigorously studied with a view to 
understanding the real biology of this cancer so as to be able 
to deploy the emerging new modalities of targeted therapy 
to address the high case fatality of the disease. However, only 
few studies have been done on ovarian cancer is sub-Saharan 
Africa, there is therefore the need for a wake up call on our 
gynecologists to evolve studies in this area so that we can also 
understand the biology of ovarian cancer in our population 
which might not necessarily be the same as in the Caucasians. 
There is also the need to urgently commence specialized 
training in gynaecological oncology to promote adequate 
and appropriate management of cases. In the meantime, 
gynecologists and other practitioners, should be conversant 
with the risk of malignancy index (RMI) scoring so that 
women assessed for adnexal mass can be referred in a timely 
and appropriate manner to centres with well-established 
gynaeoncology units. More measures should be put in 
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place to curb the menace of substandard and fake drugs at 
national and regional levels. And finally, alternative health 
financing modalities in the form of national or community 
health insurance schemes are highly desirable to assuage out 
of pocket financing and improve overall access to care for 
cancer patients in our sub-region.
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